201 related articles for article (PubMed ID: 16549920)
1. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.
Nash P; Thaçi D; Behrens F; Falk F; Kaltwasser JP
Dermatology; 2006; 212(3):238-49. PubMed ID: 16549920
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
Kaltwasser JP; Nash P; Gladman D; Rosen CF; Behrens F; Jones P; Wollenhaupt J; Falk FG; Mease P;
Arthritis Rheum; 2004 Jun; 50(6):1939-50. PubMed ID: 15188371
[TBL] [Abstract][Full Text] [Related]
3. Leflunomide in psoriatic arthritis.
Kaltwasser JP
Autoimmun Rev; 2007 Sep; 6(8):511-4. PubMed ID: 17854740
[TBL] [Abstract][Full Text] [Related]
4. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide in psoriasis and psoriatic arthritis: a preliminary study.
Thami GP; Garg G
Arch Dermatol; 2004 Oct; 140(10):1288-9. PubMed ID: 15492204
[No Abstract] [Full Text] [Related]
6. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
[TBL] [Abstract][Full Text] [Related]
7. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
[TBL] [Abstract][Full Text] [Related]
8. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
9. [Results of leflunomide treatment of psoriatic arthritis].
Pchelintseva AO; Korotaeva TV; Godzenko AA; Korsakova IuL; Stanislav ML; Denisov LN
Ter Arkh; 2007; 79(8):22-8. PubMed ID: 17926466
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
Poór G; Strand V;
Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
[TBL] [Abstract][Full Text] [Related]
11. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
12. Leflunomide: new indication. In psoriatic rheumatism: too many risks, too little efficacy.
Prescrire Int; 2005 Aug; 14(78):123-6. PubMed ID: 16106593
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide in the treatment of psoriasis: results of a phase II open trial.
Tlacuilo-Parra JA; Guevara-Gutiérrez E; Rodríguez-Castellanos MA; Ornelas-Aguirre JM; Barba-Gómez JF; Salazar-Páramo M
Br J Dermatol; 2004 May; 150(5):970-6. PubMed ID: 15149511
[TBL] [Abstract][Full Text] [Related]
14. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe psoriasis and psoriatic arthritis with leflunomide.
Reich K; Hummel KM; Beckmann I; Mössner R; Neumann C
Br J Dermatol; 2002 Feb; 146(2):335-6. PubMed ID: 11903256
[No Abstract] [Full Text] [Related]
16. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
18. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
20. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]